A Study to Determine the Safety and Efficacy of NT-501 With MHFM
A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2
Sponsor: Neurotech Pharmaceuticals
This PHASE3 trial investigates Macular Telangiectasia Type 2 and is currently ongoing. Neurotech Pharmaceuticals leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Not Yet Recruiting PHASE3
▶ Show 3 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Neurotech Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .